Mikael Landén, MD, PhD: A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors

Name: Mikael Landén, MD, PhD: A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors
SKU: 2915
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 39 No. 1 Articles Tags: depressive-disorder, drug-effects, medworks-media, michael-e-thase, mikael-landen, premenstrual-syndrome, psychopharmacology-bulletin, serotonin-antagonist, serotonin-antagonists, serotonin-receptors, treatment-outcome

Description

Mikael Landén, MD, PhD: A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors

Description

Mikael Landén, MD, PhD

GENERAL PSYCHOPHARMACOLOGY

A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors

Mikael Landén, MD, PhD, and Michael E. Thase, MD

Paliperidone Double-blind, Placebo- and Active-Controlled, Study

Agomelatine for Depression in Schizophrenia by Jochen Mutschler

Vilazodone – Safety and Tolerability Profile PB VOL 44 No. 3

Euprolactinemic Gynecomastia and Galactorrhea with Risperidone-Fluvoxamine Combination by Samir Kumar Praharaj

Mikael Landén, MD, PhD: A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors

Description

Mikael Landén, MD, PhD

GENERAL PSYCHOPHARMACOLOGY

A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors

Mikael Landén, MD, PhD, and Michael E. Thase, MD

Related products

Paliperidone Double-blind, Placebo- and Active-Controlled, Study

Agomelatine for Depression in Schizophrenia by Jochen Mutschler

Vilazodone – Safety and Tolerability Profile PB VOL 44 No. 3

Euprolactinemic Gynecomastia and Galactorrhea with Risperidone-Fluvoxamine Combination by Samir Kumar Praharaj